The Medicines Company’s Curacyte Acquisition Points To A Post-Angiomax Future
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal expands TMC’s pipeline, with an eye on the antifibrinolytic market left empty by the Trasylol withdrawal.
You may also be interested in...
The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY (Part 2 Of 3)
The Medicines Company gradually has revised its business model, moving into earlier-stage research, largely through the acquisition of two biotechs in the past year.
The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY (Part 2 Of 3)
The Medicines Company gradually has revised its business model, moving into earlier-stage research, largely through the acquisition of two biotechs in the past year.
Can The Medicines Company Rebound From A Phase III Blow?
Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.